XML 33 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information
12 Months Ended
Jun. 30, 2021
Notes to Financial Statements  
Supplemental Balance Sheet Disclosures [Text Block]

Note 3. Supplemental Balance Sheet and Cash Flow Information:

 

Available-For-Sale Investments:

 

The fair value of the Company's available-for-sale equity investments as of June 30, 2021 and June 30, 2020 were $20.0 million and $87.8 million, respectively. The decrease was due to year-over-year decrease in the stock price of CCXI, which was $13.39 per share at June 30, 2021 compared to $57.54 per share at June 30, 2020. The amortized cost basis of the Company's investment in CCXI was $6.6 million and $6.6 million as of June 30, 2021 and 2020, respectively. The Company's available-for-sale debt securities as of June 30, 2021 and June 30, 2020 were $12.5 million and $36.4 million, respectively. The decrease is due to the timing of debt maturities and cash balances at the balance sheet date. 

 

Inventories:

 

Inventories consist of (in thousands):

 

  

June 30,

 
  

2021

  2020 
         

Raw materials

 $55,096  $51,530 

Finished goods(1)

  67,108   56,268 

Inventories, net

 $122,204  $107,798 

 

(1) Finished goods inventory of $5,456 and $4,646 is included within other long-term assets in the June 30, 2021 and June 30, 2020 Balance Sheets, respectively, as it forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.  

 

Property and Equipment:

 

Property and equipment consist of (in thousands):

 

  

June 30,

 
  

2021

  2020 

Cost:

        

Land

 $8,612  $8,516 

Buildings and improvements

  190,661   184,430 

Machinery, equipment and other

  198,483   153,704 

Property and equipment

  397,756   346,650 

Accumulated depreciation and amortization

  (189,849

)

  (169,821

)

Property and equipment, net

 $207,907  $176,829 

 

Intangibles assets were comprised of the following (in thousands):

 

        

June 30,

 
  

Useful Life

(years)

  

2021

  2020 
               

Developed technology

  9-15  $552,160  $434,653 

Trade names

  2-20   147,640   146,713 

Customer relationships

  7-16   232,493   211,750 

Patents

   10    2,926   2,475 
Other intangibles(1)  5-15   6,316   - 

Definite-lived intangible assets

        941,535   795,591 

Accumulated amortization

        (348,267

)

  (279,046

)

Definite-lived intangibles assets, net

        593,268   516,545 
In process research and development        22,700   - 
Total intangible assets, net       $615,968  $516,545 

 

(1) Increase in other intangibles assets is primarily due to $5.0 million recognized in intangible assets in the first quarter of fiscal 2021 for certain third party patented technology acquired.

 

Changes to the carrying amount of net intangible assets consist of (in thousands):

 

   

June 30,

 
   2021  2020 
          

Beginning balance

  $516,545  $579,429 

Acquisitions (Note 4)

   153,311   - 

Other additions

   5,912   311 

Amortization expense

   (64,940

)

  (61,095

)

Currency translation

   5,140

 

  (2,100

)

Ending balance

  $615,968  $516,545 

 

Amortization expense related to developed technologies included in cost of sales was $36.5 million, $34.5 million, and $33.3 million in fiscal 2021, 2020, and 2019, respectively. Amortization expense related to trade names, customer relationships, non-compete agreements, and patents included in selling, general and administrative expense was $28.4 million, $26.6 million, and $25.4 million, in fiscal 2021, 2020, and 2019 respectively.

 

The estimated future amortization expense for intangible assets as of June 30, 2021, excluding any possible future amortization associated with acquired IPR&D which has not met technological feasibility, is as follows (in thousands):

 

2022

 $74,482 

2023

  72,649 

2024

  69,780 

2025

  66,523 

2026

  62,739 

Thereafter

  247,095 

Total

 $593,268 

 

Changes in goodwill by segment and in total consist of (in thousands):

 

  

Protein

Sciences

  

Diagnostics &

Genomics

  

Total

 

June 30, 2019

 $377,407  $355,260  $732,667 

Acquisitions (Note 4)

  (326

)

  -   (326

)

Currency Translation

  (4,000

)

  (31

)

  (4,031

)

June 30, 2020

 $373,081  $355,229  $728,310 
Acquisitions (Note 4)  7,848   94,970   102,818 
Currency translation  11,788   151   11,939 
June 30, 2021 $392,717  $450,350  $843,067 

 

Supplemental Cash Flow Information:

 

Supplemental cash flow information was as follows (in thousands):

 

  

Year Ended June 30,

 
  

2021

  2020  2019 

Income taxes paid

 $20,952  $41,992  $36,814 

Interest paid

  13,576   18,615   21,497 

Non-cash activities:

            

Acquisition-related liabilities(1)

  23,600

 

  (2,105)  12,600 
Other intangibles(2)  4,000   -   - 

 

 

(1) Consists of holdback payments due at future dates and liabilities for contingent consideration. Amounts disclosed above represent the total non-cash change in the liability from the prior fiscal year. Further information regarding liabilities for contingent consideration can be found in Notes 4 and 5.

(2) $4.0 million of the third party patented technology acquired in fiscal 2021 was a non-cash activity within the consolidated statement of cash flows as a cash payment was not made within the fiscal year ended June 30, 2021.